Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2021

Rhea-AI Summary

Amphastar Pharmaceuticals reported net revenues of $101.7 million for Q2 2021, an 18% increase from the previous year. The company achieved a GAAP net income of $7.8 million ($0.16 per share) and an adjusted non-GAAP net income of $10.6 million ($0.21 per share). Key growth drivers included strong sales of Primatene Mist, glucagon, and epinephrine. The company also announced plans to increase its share buyback program by $20 million and refinanced $30 million of debt, enhancing financial flexibility.

Positive

• Net revenues rose to $101.7 million, an 18% year-over-year increase.
• GAAP net income for Q2 was $7.8 million, compared to a loss in the previous year.
• Adjusted non-GAAP net income increased to $10.6 million from $7.6 million year-over-year.
• Strong sales growth driven by Primatene Mist, glucagon, and epinephrine products.
• Share buyback program increased by $20 million, offering potential shareholder value.
• Successfully refinanced $30 million in debt, improving interest expenses.

Negative

• Naloxone sales decreased by 24% due to lower average selling prices and increased competition.
• Sales of other finished pharmaceutical products fell by 23% as competition returned to normal distribution levels.

Reports Net Revenues of $101.7 Million for the Three Months Ended June 30, 2021

RANCHO CUCAMONGA, CA / ACCESSWIRE / August 9, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the "Company") today reported results for the three months ended June 30, 2021.

Second Quarter Highlights

• Net revenues of $101.7 million for the second quarter
• GAAP net income of $7.8 million, or $0.16 per share, for the second quarter
• Adjusted non-GAAP net income of $10.6 million, or $0.21 per share, for the second quarter

Dr. Jack Zhang, Amphastar's President and Chief Executive Officer, commented: "Continued strong sales of glucagon, Primatene Mist^® and our epinephrine products led to another strong quarter of growth. We believe that these products will continue to drive growth as we continue to develop and realize approvals from our pipeline."

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2021				2020				2021				2020
		(in thousands, except per share data)
Net revenues		$	101,663			$	85,806			$	204,683			$	170,494
GAAP net income (loss) attributable to Amphastar		$	7,767			$	(192	)		$	12,808			$	3,757
Adjusted non-GAAP net income attributable to Amphastar*		$	10,615			$	7,610			$	24,168			$	15,993
GAAP diluted EPS attributable to Amphastar stockholders		$	0.16			$	(0.00	)		$	0.26			$	0.08
Adjusted non-GAAP diluted EPS attributable to Amphastar stockholders*		$	0.21			$	0.16			$	0.49			$	0.33

---

* Adjusted non-GAAP net income attributable to Amphastar and Adjusted non-GAAP diluted EPS attributable to Amphastar stockholders are non-GAAP financial measures. Please see the discussion in the section entitled "Non-GAAP Financial Measures" and the reconciliation of GAAP to non-GAAP financial measures in Table III of this press release.

Second Quarter Results

		Three Months Ended June 30,								Change
		2021				2020				Dollars				%
		(in thousands)
Net revenues:
Primatene Mist®		$	16,680			$	12,468			$	4,212				34	%
Glucagon			12,131				-				12,131				N/A
Lidocaine			11,594				7,608				3,986				52	%
Phytonadione			10,421				10,689				(268	)			(3	)%
Enoxaparin			9,328				10,218				(890	)			(9	)%
Epinephrine			9,192				6,957				2,235				32	%
Naloxone			6,625				8,723				(2,098	)			(24	)%
Other finished pharmaceutical products			18,751				24,272				(5,521	)			(23	)%
Total finished pharmaceutical products net revenues		$	94,722			$	80,935			$	13,787				17	%
API			6,941				4,871				2,070				42	%
Total net revenues		$	101,663			$	85,806			$	15,857				18	%

Changes in net revenues were primarily driven by:

• Primatene Mist ^® increased volumes resulting from:
  • The continued success of our nationwide television, radio, and digital marketing campaign
  • An increase in our distribution channels throughout 2020 and 2021
• Glucagon for injection emergency kit which was launched in the first quarter of 2021
• Lidocaine and epinephrine sales increased due to higher demand as a result of a market shortage
• Naloxone sales decreased due to lower average selling price resulting from increased competition
• Other finished pharmaceutical product sales decreased due to lower demand, largely due to competitors returning to their normal distribution levels

		Three Months Ended June 30,								Change
		2021				2020				Dollars				%
		(in thousands)
Net revenues		$	101,663			$	85,806			$	15,857				18	%
Cost of revenues			54,287				52,629				1,658				3	%
Gross profit		$	47,376			$	33,177			$	14,199				43	%
as % of net revenues			47	%			39	%

Changes in the cost of revenues and the resulting increase in gross margin were primarily driven by:

• Increased sales of higher margin products such as Primatene Mist ^® , epinephrine injection multi-dose vials, and glucagon
• Partially offset by increased cost for heparin, which is used as the starting material for enoxaparin

		Three Months Ended
		June 30,								Change
		2021				2020				Dollars				%
		(in thousands)
Selling, distribution, and marketing		$	4,129			$	4,026			$	103				3	%
General and administrative			14,565				15,924				(1,359	)			(9	)%
Research and development			18,122				16,149				1,973				12	%
Non-operating income, net			3,657				1,418				2,239				158	%

• Selling, distribution, and marketing expenses increased due to the marketing and distribution expenses for Primatene Mist ^®
• General and administrative expenses decreased primarily due to cash compensation and share-based compensation expense relating to the separation agreement that we entered into with a former executive during the second quarter of 2020, which was partially offset by an increase in legal expenses in the second quarter of 2021
• Research and development expenses increased due to an increase in salaries and personnel-related expenses as well as an increase in depreciation expense
• Non-operating income, net, increased as a result of a reduction in the accrual for the settlement of the Aventis litigation during the quarter by $2.7 million based on the settlement agreement with Aventis during the quarter

Cash flow provided by operating activities for the six months ended June 30, 2021, was $55.0 million.

Share Buyback Program

On August 3, 2021, the Company's Board of Directors authorized an increase of $20 million to the Company's share buyback program, which is expected to continue for an indefinite period of time. The primary goal of the program is to offset dilution created by the Company's equity compensation programs.

Purchases may be made through the open market and private block transactions pursuant to Rule 10b5-1 plans, privately negotiated transactions, or other means, as determined by the Company's management and in accordance with the requirements of the Securities and Exchange Commission and applicable laws.

The timing and actual number of shares repurchased will depend on a variety of factors including price, corporate and regulatory requirements, and other conditions.

Debt Refinancing

On August 4, 2021, the Company refinanced $30 million of outstanding debt by entering into a $140 million credit facility consisting of a $70 million term loan and a $70 million revolving line of credit.

Bill Peters, Chief Financial Officer, commented, "Entering into this credit agreement allows us to lower our interest expense while enabling financial flexibility for future growth needs."

Capital One and East West Bank were the joint lead arrangers for this syndicated debt offering, and Wells Fargo Bank, Cathay Bank, and Fifth Third Bank participated as lenders.

Pipeline Information

The Company currently has five ANDAs on file with the FDA targeting products with a market size of approximately $2.5 billion, three biosimilar products in development targeting products with a market size of approximately $13 billion, and seven generic products in development targeting products with a market size of approximately $10 billion. This market information is based on IQVIA data for the 12 months ended June 30, 2021. The Company is currently developing multiple proprietary products with injectable and intranasal dosage forms.

Amphastar's Chinese subsidiary, ANP, currently has 17 Drug Master Files, or DMFs, on file with the FDA and is developing several additional DMFs.

Company Information

Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products. Additionally, the Company sells insulin API products. Most of the Company's finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. More information and resources are available at www.amphastar.com .

Amphastar's logo and other trademarks or service marks of Amphastar, including, but not limited to Amphastar ^® , Primatene Mist ^® , Amphadase ^® , and Cortrosyn ^® , are the property of Amphastar.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are prepared and presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company is disclosing non-GAAP financial measures when providing financial results. The Company believes that an evaluation of its ongoing operations (and comparisons of its current operations with historical and future operations) would be difficult if the disclosure of its financial results were limited to financial measures prepared only in accordance with GAAP. As a result, the Company is disclosing certain non-GAAP results, including (i) Adjusted non-GAAP net income (loss) attributed to Amphastar and (ii) Adjusted non-GAAP diluted EPS attributed to Amphastar's stockholders, which exclude amortization expense, share-based compensation, impairment charges, executive severance expense, and legal settlements, in order to supplement investors' and other readers' understanding and assessment of the Company's financial performance because the Company's management uses these measures internally for forecasting, budgeting, and measuring its operating performance. Whenever the Company uses such non-GAAP measures, it will provide a reconciliation of non-GAAP financial measures to their most directly comparable GAAP financial measures. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures set forth below and should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP.

Conference Call Information

The Company will hold a conference call to discuss its financial results today, August 9, 2021, at 2:00 p.m. Pacific Time.

To access the conference call, dial toll-free (877) 407-0989 or (201) 389-0921 for international callers, five minutes before the conference.

The call can also be accessed on the Investors page on the Company's website at www.amphastar.com .

Forward-Looking Statements

All statements in this press release and in the conference call referenced above that are not historical are forward-looking statements, including, among other things, statements relating to our expectations regarding future financial performance, backlog, sales and marketing of our products, market size and growth, product development, the timing of FDA filings or approvals, including the DMFs of ANP, the timing of product launches, acquisitions and other matters related to our pipeline of product candidates, our share buyback program and other future events, such as the impact of the COVID-19 pandemic including its variants and related responses of business and governments to the pandemic on our operations and personnel, and on commercial activity and demand across our business operations and results of operations. These statements are not facts but rather are based on Amphastar's historical performance and our current expectations, estimates, and projections regarding our business, operations, and other similar or related factors. Words such as "may," "might," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plan," "project," "believe," "estimate," and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Amphastar's control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Amphastar's filings with the Securities and Exchange Commission, including in our Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on March 15, 2021. In particular, the extent of COVID-19's impact on our business will depend on several factors, including the severity, duration and extent of the pandemic including its variants, as well as actions taken by governments, businesses, and consumers in response to the pandemic, all of which continue to evolve and remain uncertain at this time. You can locate these reports through our website at http://ir.amphastar.com and on the SEC's website at www.sec.gov. The forward-looking statements in this release speak only as of the date of the release. Amphastar undertakes no obligation to revise or update information or any forward-looking statements in this press release or the conference call referenced above to reflect events or circumstances in the future, even if new information becomes available or if subsequent events cause our expectations to change.

Contact Information:

Amphastar Pharmaceuticals, Inc.
Bill Peters
Chief Financial Officer
(909) 980-9484

Table I
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Statement of Operations
(Unaudited; in thousands, except per share data)

		Three Months Ended June 30,								Six Months Ended June 30,
		2021				2020				2021				2020
Net revenues		$	101,663			$	85,806			$	204,683			$	170,494
Cost of revenues			54,287				52,629				112,361				100,494
Gross profit			47,376				33,177				92,322				70,000
Operating expenses:
Selling, distribution, and marketing			4,129				4,026				8,666				7,320
General and administrative			14,565				15,924				29,903				26,670
Research and development			18,122				16,149				32,887				31,452
Total operating expenses			36,816				36,099				71,456				65,442
Income (loss) from operations			10,560				(2,922	)			20,866				4,558
Non-operating income (expense), net			3,657				1,418				(1,535	)			(257	)
Income (loss) before income taxes			14,217				(1,504	)			19,331				4,301
Income tax provision (benefit)			5,595				(75	)			6,750				2,205
Net income (loss)		$	8,622			$	(1,429	)		$	12,581			$	2,096
Net income (loss) attributable to non-controlling interests		$	855			$	(1,237	)		$	(227	)		$	(1,661	)
Net income (loss) attributable to Amphastar		$	7,767			$	(192	)		$	12,808			$	3,757
Net income (loss) per share attributable to Amphastar stockholders:
Basic		$	0.16			$	(0.00	)		$	0.27			$	0.08
Diluted		$	0.16			$	(0.00	)		$	0.26			$	0.08
Weighted-average shares used to compute net income (loss) per share attributable to Amphastar stockholders:
Basic			47,731				46,753				47,626				46,581
Diluted			49,552				46,753				49,535				48,458

Table II
Amphastar Pharmaceuticals, Inc.
Condensed Consolidated Balance Sheets
(Unaudited; in thousands, except share data)

		June 30,				December 31,
		2021				2020
ASSETS
Current assets:
Cash and cash equivalents		$	105,432			$	92,642
Restricted cash			19,159				1,865
Short-term investments			11,745				12,977
Restricted short-term investments			2,200				2,200
Accounts receivable, net			67,893				66,005
Inventories			97,931				96,831
Income tax refunds and deposits			718				385
Prepaid expenses and other assets			5,895				6,777
Total current assets			310,973				279,682
Property, plant, and equipment, net			252,590				260,055
Finance lease right-of-use assets			540				612
Operating lease right-of-use assets			27,169				20,042
Goodwill and intangible assets, net			40,049				40,615
Other assets			9,444				5,250
Deferred tax assets			24,980				24,980
Total assets		$	665,745			$	631,236
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities		$	109,604			$	95,504
Income taxes payable			3,631				1,077
Current portion of long-term debt			8,077				12,263
Current portion of operating lease liabilities			3,237				3,357
Total current liabilities			124,549				112,201
Long-term reserve for income tax liabilities			4,709				4,709
Long-term debt, net of current portion			30,460				34,186
Long-term operating lease liabilities, net of current portion			24,555				17,464
Deferred tax liabilities			765				741
Other long-term liabilities			13,484				13,212
Total liabilities			198,522				182,513
Commitments and contingencies
Stockholders' equity:
Preferred stock: par value $0.0001; 20,000,000 shares authorized; no shares issued and outstanding			-				-
Common stock: par value $0.0001; 300,000,000 shares authorized; 55,736,209 and 47,983,549 shares issued and outstanding as of June 30, 2021 and 54,760,922 and 47,495,439 shares issued and outstanding as of December 31, 2020, respectively			6				5
Additional paid-in capital			427,301				410,061
Retained earnings			130,581				117,773
Accumulated other comprehensive loss			(4,931	)			(3,721	)
Treasury stock			(130,964	)			(121,812	)
Total Amphastar Pharmaceuticals, Inc. stockholders' equity			421,993				402,306
Non-controlling interests			45,230				46,417
Total equity			467,223				448,723
Total liabilities and stockholders' equity		$	665,745			$	631,236

Table III
Amphastar Pharmaceuticals, Inc.
Reconciliation of Non-GAAP Measures
(Unaudited; in thousands, except per share data)

		Three Months Ended								Six Months Ended
		June 30,								June 30,
		2021				2020				2021				2020
GAAP net income (loss)		$	8,622			$	(1,429	)		$	12,581			$	2,096
Adjusted for:
Intangible amortization			277				251				553				509
Share-based compensation			6,084				4,194				10,918				9,476
Impairment of long-lived assets			308				16				314				30
Expense related to executive separation agreement			-				4,869				-				4,869
Reserves for litigation and settlements			(2,704	)			-				2,991				-
Income tax (benefit) provision on pre-tax adjustments			(306	)			(1,445	)			(2,535	)			(2,449	)
Non-GAAP net income		$	12,281			$	6,456			$	24,822			$	14,531
Non-GAAP net income (loss) attributable to non-controlling interests		$	1,666			$	(1,154	)		$	654			$	(1,462	)
Non-GAAP net income attributable to Amphastar		$	10,615			$	7,610			$	24,168			$	15,993
Non-GAAP net income per share attributable to Amphastar stockholders:
Basic		$	0.22			$	0.16			$	0.51			$	0.34
Diluted		$	0.21			$	0.16			$	0.49			$	0.33
Weighted-average shares used to compute non-GAAP net income per share attributable to Amphastar stockholders:
Basic			47,731				46,753				47,626				46,581
Diluted			49,552				48,668				49,535				48,458

		Three Months Ended June 30, 2021
		Cost of revenue				Selling, distribution and marketing				General and administrative				Research and development				Non-operating income (expense), net				Income tax provision (benefit)				Non-controlling interest adjustment
GAAP		$	54,287			$	4,129			$	14,565			$	18,122			$	3,657			$	5,595			$	855
Intangible amortization			(244	)			-				(33	)			-				-				-				11
Share-based compensation			(932	)			(147	)			(4,568	)			(437	)			-				-				791
Impairment of long-lived assets			(84	)			-				(2	)			(222	)			-				-				1
Reserves for litigation and settlements			-				-				-				-				(2,704	)			-				-
Income tax provision (benefit) on pre-tax adjustments			-				-				-				-				-				306				8
Non-GAAP		$	53,027			$	3,982			$	9,962			$	17,463			$	953			$	5,901			$	1,666

Reconciliation of Non-GAAP Measures (continued)

		Three Months Ended June 30, 2020
		Cost of revenue				Selling, distribution and marketing				General and administrative				Research and development				Non- operating income (expense), net				Income tax provision (benefit)				Non-Controlling interest adjustment
GAAP		$	52,629			$	4,026			$	15,924			$	16,149			$	1,418			$	(75	)		$	(1,237	)
Intangible amortization			(217	)			-				(34	)			-				-				-				11
Share-based compensation			(970	)			(123	)			(2,733	)			(368	)			-				-				86
Impairment of long-lived assets			(3	)			-				(13	)			-				-				-				6
Expense related to executive separation agreement			-				-				(4,869	)			-				-				-				-
Income tax provision (benefit) on pre-tax adjustments			-				-				-				-				-				1,445				(20	)
Non-GAAP		$	51,439			$	3,903			$	8,275			$	15,781			$	1,418			$	1,370			$	(1,154	)

		Six Months Ended June 30, 2021
		Cost of revenue				Selling, distribution and marketing				General and administrative				Research and development				Non-operating income (expense), net				Income tax provision (benefit)				Non-controlling interest adjustment
GAAP		$	112,361			$	8,666			$	29,903			$	32,887			$	(1,535	)		$	6,750			$	(227	)
Intangible amortization			(486	)			-				(67	)			-				-				-				22
Share-based compensation			(2,078	)			(274	)			(7,536	)			(1,030	)			-				-				862
Impairment of long-lived assets			(84	)			-				(8	)			(222	)			-				-				3
Reserves for litigation and settlements			-				-				(1,295	)			-				1,696				-				-
Income tax provision (benefit) on pre-tax adjustments			-				-				-				-				-				2,535				(6	)
Non-GAAP		$	109,713			$	8,392			$	20,997			$	31,635			$	161			$	9,285			$	654

		Six Months Ended June 30, 2020
		Cost of revenue				Selling, distribution and marketing				General and administrative				Research and development				Non-operating income (expense), net				Income tax provision (benefit)				Non-controlling interest adjustment
GAAP		$	100,494			$	7,320			$	26,670			$	31,452			$	(257	)		$	2,205			$	(1,661	)
Intangible amortization			(441	)			-				(68	)			-				-				-				22
Share-based compensation			(2,329	)			(230	)			(5,952	)			(965	)			-				-				213
Impairment of long-lived assets			(13	)			-				(17	)			-				-				-				7
Expense related to executive separation agreement			-				-				(4,869	)			-				-				-				-
Income tax provision (benefit) on pre-tax adjustments			-				-				-				-				-				2,449				(43	)
Non-GAAP		$	97,711			$	7,090			$	15,764			$	30,487			$	(257	)		$	4,654			$	(1,462	)

SOURCE: Amphastar Pharmaceuticals, Inc.

View source version on accesswire.com:
https://www.accesswire.com/658788/Amphastar-Pharmaceuticals-Reports-Financial-Results-for-the-Three-Months-Ended-June-30-2021

FAQ

What were Amphastar's net revenues for Q2 2021?

Amphastar's net revenues were $101.7 million for the three months ended June 30, 2021.

What was Amphastar's adjusted non-GAAP net income for Q2 2021?

The adjusted non-GAAP net income for Q2 2021 was $10.6 million.

How did Amphastar's revenue compare to Q2 2020?

Net revenues increased by 18% compared to Q2 2020.

What are the key growth drivers for Amphastar in Q2 2021?

The key growth drivers included strong sales of Primatene Mist, glucagon, and epinephrine products.

How much did Amphastar increase its share buyback program by?

Amphastar increased its share buyback program by $20 million.

What debt refinancing actions did Amphastar take in August 2021?

Amphastar refinanced $30 million of outstanding debt by entering into a $140 million credit facility.